Browsing by Author "Xu, Yuan"

An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.

Wei, Qingyi; Zhang, Ruoxin; Jia, Ming; Xu, Yuan; Qian, Danwen; Wang, Mengyun; Zhu, Meiling; ... (9 authors) (International journal of cancer, 2018-03)

Platinum-based chemotherapy (PBC) in combination with the 3rd generation drugs is the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy is severely hampered by grade ...

Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.

Wei, Qingyi; Zhang, Ruoxin; Jia, Ming; Xue, Huijing; Xu, Yuan; Wang, Mengyun; Zhu, Meiling; ... (9 authors) (Scientific reports, 2017-09-06)

Nucleotide excision repair (NER) plays a vital role in platinum-induced DNA damage during chemotherapy. We hypothesize that regulatory single nucleotide polymorphisms (rSNPs) of the core NER genes modulate clinical outcome ...

Variants in Notch signalling pathway genes, PSEN1 and MAML2, predict overall survival in Chinese patients with epithelial ovarian cancer.

Wei, Qingyi; Xu, Yuan; Cheng, Lei; Dai, Hongji; Zhang, Ruoxin; Wang, Mengyun; Shi, Tingyan; ... (9 authors) (Journal of cellular and molecular medicine, 2018-10)

To identify genetic variants in Notch signalling pathway genes that may predict survival of Han Chinese patients with epithelial ovarian cancer (EOC), we analysed a total of 1273 single nucleotide polymorphisms (SNPs) within ...